Metabolic syndrome as a prognostic factor in advanced pancreatic cancer: a predictive model and chemotherapy evaluation
MetS and distant metastasis significantly impact PDAC prognosis. Patients without MetS benefit more from specific chemotherapy regimens. Our predictive model may aid personalized treatment strategies.
Authors
- Yongfu Zhao (ORCID: https://orcid.org/0000-0003-2639-0820)
- Huiting Deng (ORCID: https://orcid.org/0000-0002-1143-271X)
- Jianbiao Li (ORCID: https://orcid.org/0000-0002-8097-8150)
- Jingchang Zhang (ORCID: https://orcid.org/0000-0002-6523-5201)
- Ye Zhang (ORCID: https://orcid.org/0000-0003-4157-8696)
Institutions
- Tianjin University of Technology (CN)
- Tianjin University (CN)
- Tianjin Third Central Hospital (CN)
- Tianjin Nankai Hospital (CN)
- Tianjin Infectious Diseases Hospital (CN)
- Cell Technology (China) (HK)
- Tianjin Fire Research Institute (CN)
- Integrative Medicine Institute (US)
- First Affiliated Hospital of Zhengzhou University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1186/s12957-025-03940-w
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Youth Science Foundation
- Zhengzhou University